Cessatech reports first patient dosed in pivotal trial of lead product candidate
· First patient has been dosed in pivotal trial of lead candidate CT001 · The pivotal trial, trial 0205, will investigate the postoperative analgesic efficacy of CT001, in adult participants following impacted mandibular third molar extraction, a randomised, double-blind placebo controlled trial with 220 patients. · Patient recruitment has now started, and we anticipate to finalise recruitment by the first part of 2023.Cessatech A/S announces that the pivotal trial 0205 has now been initiated with the dosing of the first patient. The trial will investigate the postoperative analgesic